Monthly Prescribing Reference

Zyprexa Intramuscular

Zyprexa Intramuscular Warnings/Precautions Warnings/Precautions Relprevv: post-injection delirum/sedation syndrome: monitor after each injection. Elderly with dementia-related psychosis (not approved ...
Morningstar

Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed

The new data were showcased in one of ten schizophrenia-related posters presented by Medincell’s partner, Teva, at the 2025 Psych Congress, held from September 17 to 21 in San Diego, California ...
Business Wire

Medincell’s partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial ...
Nasdaq

Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed

(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...
Reuters

US panel backs new form of Lilly schizophrenia drug

SILVER SPRING, Md., Feb 6 (Reuters) - A U.S. advisory panel on Wednesday backed Eli Lilly and Co's proposed long-acting form of schizophrenia drug Zyprexa. Sign up here. Advisers to the Food and Drug ...
Monthly Prescribing Reference

Zyprexa Zydis

Olanzapine 5mg, 10mg, 15mg, 20mg; orally-disintegrating tabs; contains phenylalanine. Bipolar disorder: Monotherapy: initially 10–15mg once daily; may increase by 5mg/day. Concomitant lithium or ...